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Abstract 
Purpose: To assess changes in the comprehensive stress state of patients with diabetic ketoacidosis 
(DKA) following treatment with insulin infusion pump. 
Methods: A total of 240 patients suffering from DKA who received treatment at The First Affiliated 
Hospital of Zhengzhou University from Feb. 2011 to Feb. 2014 were selected randomly and divided into 
a control group (120 cases), administered continuous intravenous insulin, and a treatment group (120 
cases), administered insulin with an infusion pump. Relevant diabetes-associated serum indices, 
oxidative stress and stress hormone levels were compared between the groups at different time points.  
Results: Levels of glycosylated haemoglobin (HbAlc), fasting blood glucose (FBG) and anion gap (AG) 
were lower (p < 0.05) in the treatment group than in the control group at various time points. Carbon 
dioxide combining power (CO2-CP) and C-reactive peptide levels in the treatment group were higher (p 
< 0.05) than those of the control group at different time points. Except for the level of methane 
dicarboxylic aldehyde (MDA), the values of other oxidative stress indices were higher (p < 0.05) in the 
treatment group than in the control group at various time points. Moreover, the treatment group had 
lower serum cortisol (Cor) and noradrenalin (NA) levels and higher levels of free triiodothyronine (FT3), 
free thyroxine (FT4) and thyroid-stimulating hormone (TSH) than those of (p < 0.05). 
Conclusion: Insulin pump infusion effectively relieves the comprehensive stress state of patients 
suffering from DKA, and its therapeutic effect is superior to that of continuous instillation of low-dose 
insulin. 
 
Keywords: Diabetic ketoacidosis, Insulin pump, Comprehensive stress state, Blood glucose, Carbon 
dioxide combining power, C-reactive peptide 
 
Tropical Journal  of Pharmaceutical Research is indexed by Science Citation Index (SciSearch), Scopus, 
International Pharmaceutical Abstract, Chemical Abstracts, Embase, Index Copernicus, EBSCO, African 
Index Medicus, JournalSeek, Journal Citation Reports/Science Edition, Directory of Open Access Journals 




Diabetic ketoacidosis (DKA) refers to 
pathological changes, such as hyperglycaemia, 
hyperketonaemia, electrolyte disturbance, 
metabolic acidosis and ketonuria, as a result of 
insulin insufficiency under the effects of acute 
infection, improper treatment or metabolic 
disturbances induced by a diet failing to control 
diabetes [1,2]. Insulin insufficiency is the leading 
cause of DKA. Thus, the key to treating DKA is to 
correct the acidosis and hyperketonaemia 
induced by acute metabolic disturbance by 
providing low-dose insulin [3,4]. 
 
The conventional therapy for DKA is continuous 
intravenous injection of low-dose insulin, but it is 
associated with complications, such as a slow 
recovery of blood glucose levels, a high risk of 
hypoglycaemia, and slow negative conversion of 
ketone bodies [5]. Insulin instilled intravenously 
at a concentration of 20 % was found to be 
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absorbed by the wall of the infusion tube; thus, 
the curative effect of insulin administered via this 
method is decreased by absorption [6]. Currently, 
an insulin pump is considered an effective 
treatment for DKA [7,8]. Such a system consists 
of a pump, small injector and infusion tube that 
continuously infuses insulin beneath the skin of 
patients to maintain a stable blood glucose level 
by simulating pancreatic secretion. 
Consequently, patients absorb insulin 
continuously, thereby maintaining a highly stable 
blood insulin concentration. Moreover, the 
primary dose prior to eating can be adjusted 
according to disease conditions and blood 
glucose levels. Using an insulin pump, blood 
glucose is maintained at a normal level, and 
glycosylated haemoglobin (HbAlc) and the 
incidence of hypoglycaemia are reduced 
significantly [9,10]. 
 
In a DKA state, acute hyperglycaemia and 
fluctuations in blood glucose levels can result in 
the changes in oxidative stress and stress 
hormone levels [11]. This study explored the 
effects of insulin pump treatment on the 







A total of 240 patients who were suffering from 
DKA who received treatment at the First Affiliated 
Hospital of Zhengzhou University, Zhengzhou, 
Henan, China between February 2011 and 
February 2014 were selected as research 
subjects. The study was approved by the Medical 
Ethics Committee of The First Affiliated Hospital 
of Zhengzhou University (approval number: 
JWJ20150627), and conformed to the principles 
of the Declaration of Helsinki [12]. Patients aged 
35–65 years who met the diagnostic criteria for 
DKA and had a blood glucose level > 13.9 
mmol/L, blood pH < 7.35, ketonuria positivity, 
anion gap (AG) > 16 mmol/L and HCO3  level < 
18 mmol/L were included. Patients with DKA 
induced by acute cardiovascular and 
cerebrovascular diseases, gastrointestinal 
haemorrhage, major surgery or pregnancy were 
excluded. Patients (N = 240) were divided 
randomly into treatment and control groups using 




Patients in the two groups were administered 
supportive treatment, such as fluid infusion, acid-
base imbalance correction and electrolyte 
disturbance correction, upon admission to the 
hospital. Patients in the control group were 
treated with intravenous instillation of low-dose 
insulin (4–6 U/h), whereas patients in the 
treatment group were treated with intravenous 
insulin administered by an insulin pump at a rate 
of 4–6 U/h. The peripheral blood glucose level 
was measured before eating, 2 h after eating, 
and before bedtime. The dose of insulin was 




Blood gas analysis, measuring carbon dioxide 
combining power (CO2-CP) and AG levels, was 
performed in all patients at admission and 2 h 
and 24 h after treatment. Elbow venous blood (5 
mL) was drawn from each patient at different 
time points. The blood samples were centrifuged, 
and the supernatant was used for determination 
of levels of HbAlc, fasting blood glucose (FBG)) 
and C-reactive peptide and oxidative stress-
associated indices, including superoxide 
dismutase (SOD), malondialdehyde (MDA), 
glutathione peroxidase (GSH-PX) and the total 
antioxidant capacity (TAC), as well as levels of 
stress-associated hormones, including cortisol 
(Cor), noradrenalin (NA), free triiodothyronine 
(FT3), free thyroxine (FT4) and thyroid-
stimulating hormone (TSH). 
 
The FBG level was measured using a fully 
automatic biochemical analyser. The HbAlc level 
was measured using high-performance liquid 
chromatography. Levels of C-reactive peptide, 
Cor, SOD, MDA, GSH-PX and TAC were 
measured using chemiluminescence methods. 
Levels of the other hormones were measured 





Data were analysed using SPSS software (ver. 
19.0) and expressed as mean ± SD. 
Comparisons between groups were performed 
using independent-sample t-tests. Enumerated 
data were compared using χ2 tests. Differences 







The control group consisted of 64 males and 56 
females, with an average age of 52.63 ± 7.21 
years, body mass index (BMI) of 23.92 ± 2.03 
kg/m2 and duration of diabetes of 7.65 ± 2.13 
years. There were 62 cases of hypertension and 
34 of coronary heart disease. The treatment 
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group consisted of 66 males and 54 females, 
with an average age of 53.14 ± 7.28 years, BMI 
of 24.03 ± 2.12 kg/m2 and duration of diabetes of 
7.87 ± 2.08 years. There were 66 cases of 
hypertension and 36 of coronary heart disease. 
Differences in sex, age, BMI and duration of 
diabetes between the two groups were not 
statistically significant; thus, the results were 
comparable. 
 
Diabetic indices before and after treatment 
 
No significant differences were observed in any 
of the indices between the two groups (p > 0.05). 
Levels of HbAlc, FBG and AG were much lower, 
and the CO2-CP and C-reactive peptide levels 
higher, in the treatment group than the control 
group 2 h and 24 h after treatment (Table 1). 
 
Serum oxidative stress-associated indices  
 
Levels of SOD, GSH-PX and TAC showed no 
significant differences between the two groups 
before treatment (p > 0.05). At 2 h and 24 h after 
treatment, the serum MDA level was much lower, 
and SOD, GSH-PX and TAC levels much higher, 
in the treatment group than the control group (p < 
0.05; Table 2). 
 
Stress hormone levels before and after 
treatment 
 
Differences in levels of serum Cor, NA, FT3, FT4 
and TSH between the two groups were not 
statistically significant before treatment (p > 
0.05). Levels of serum Cor and NA were much 
lower, whereas the levels of FT3, FT4 and TSH 
were much higher, in the treatment group than 
the control group (p < 0.05) 2 h and 24 h after 




DKA is a complication commonly observed in 
patients suffering from diabetes. Epidemiological 
investigations suggest that the incidence of DKA 
is between 15 and 45 %. DKA occurs when 
severe insulin insufficiency significantly weakens 
biological functions,  
 
    Table 1: Diabetic indices before and after treatment (mean ± SD) 
 
Parameter Time Control group Treatment group 
HbAlc (%) 
0 h 14.03±3.92 13.86±3.74 
2 h 12.26±3.62 9.01±3.66* 
24 h 7.11±2.06 5.22±1.16* 
CO2-CP (mM) 
0 h 6.76±3.51 6.78±3.47 
2 h 8.92±3.68 12.02±3.61* 
24 h 18.31±3.06 0.47±0.17* 
FBG (mM) 
0 h 18.7±8.13 18.90±8.02 
2 h 17.08±6.72 16.33±4.27* 
24 h 7.67±3.53 6.85±2.01* 
AG (mM) 
0 h 33.46±8.37 33.10±8.13 
2 h 27.66±8.11 24.04±8.46* 
24 h 21.62±7.04 17.66±6.03* 
C-reactive peptide 
(ng/mL) 
0 h 0.05±0.03 0.05±0.04 
2 h 0.23±0.13 21.37±3.16* 
24 h 0.73±0.26 1.14±0.43* 
   Note: * Significant difference (p < 0.05) versus control group 
 
Table 2: Serum oxidative stress-associated indices before and after treatment (mean ± SD) 
 
Parameter Time Control group Treatment group 
SOD (U/L) 
0 h 22.61±7.63 22.96±7.70 
2 h 24.73±7.61 26.61±7.45* 
24 h 27.14±7.32 31.32±8.01* 
MDA (nmol/mL) 
0 h 8.97±2.11 8.83±2.48 
2 h 8.97±2.12 6.87±1.86* 
24 h 7.85±2.15 4.06±1.92* 
GSH-PX(U/mL) 
0 h 73.64±9.67 73.04±8.04 
2 h 75.65±9.33 82.35±8.25* 
24 h 86.05±9.16 95.43±9.04* 
TAC (U/mL) 
0 h 17.56±5.18 17.87±5.17 
2 h 21.72±5.11 24.23±6.04* 
24 h 22.35±5.34 26.96±4.32* 
   * Significant difference (p < 0.05) versus the control group. 
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   Table 3: Stress hormones before and after treatment (mean ± SD) 
 
Parameter Time Control group Treatment group 
Cor (nmol/L) 
0 h 865.46±312.58 851.71±306.66 
2 h 813.62±261.38 721.45±264.70* 
24 h 602.01±192.46 478.32±131.61* 
NA (ng/L) 
0 h 817.96±413.65 823.18±386.32 
2 h 754.73±362.52 674.62±231.62* 
24 h 531.67±205.16 403.19±131.47* 
FT3 (pmol/L) 
0 h 2.85±1.22 2.81±1.37 
2 h 2.97±1.26 3.25±1.43* 
24 h 3.98±1.02 4.20±1.38* 
FT4 (pmol/L) 
0 h 11.61±3.53 11.67±3.30 
2 h 12.52±3.61 13.48±3.16* 
24 h 14.23±3.01 15.32±3.11* 
TSH (mIU/L) 
0 h 1.80±0.76 1.87±0.78 
2 h 1.93±0.73 2.01±0.76* 
24 h 2.33±0.87 2.62±0.85* 
     * Significant difference (p < 0.05) versus the control group 
 
such as cell differentiation and glucose 
utilisation, thereby increasing blood glucose 
levels. This resulting energy insufficiency 
accelerates cell differentiation and increases 
blood and urinary ketone levels, ultimately 
inducing the clinical symptoms and signs of 
metabolic acidosis [13,14]. Thus, the key to 
treating DKA is rapid control of the disease 
condition, and insulin treatment is absolutely 
necessary [15]. Low-dose insulin has great 
significance in the treatment of DKA. One study 
[16] suggested that early application of insulin 
effectively controlled acute onset of DKA by 
decreasing blood glucose levels, regulating the 
amplification cascade of inflammatory factors 
and relieving the stress state. Infusion of insulin 
using a insulin pump can help maintain stable 
blood insulin levels by controlling the infusion 
rate. Compared with conventional intravenous 
instillation of insulin, it can lower the level of 
blood glucose level more gradually and prevent 
hypoglycaemia [17]. 
 
In this study, the comprehensive stress state of 
patients with DKA was evaluated before and 
after micropump treatment, and the curative 
effect of the micropump was compared with that 
of intravenous instillation of low-dose insulin. The 
results demonstrated that the levels of HbAlc, 
FBG, and AG were significantly lower, and the 
levels of CO2-CP and C-reactive peptide much 
higher, in the treatment group than the control 
group, suggesting that insulin pump treatment 
induced a more rapid and stronger curative 
effect. 
 
Patients with DKA demonstrate oxidative 
damage and high stress hormone levels. It has 
been found that the high expression of 
proinflammatory factors in patients with DKA can 
induce synthesis of acute-phase proteins, 
proliferation and differentiation of T cells, mass 
synthesis of reactive oxygen intermediates, 
leading to lipid peroxidation, and stress reactions 
[18]. Activation of the hypothalamus-pituitary-
adrenal gland, gonads, thyroid gland axis, and 
sympathetic nervous system are also involved in 
the common stress reaction observed in DKA. 
Under DKA conditions, the body produces stress 
hormones such as epinephrine, noradrenalin and 
glucocorticoids to initiate stress defence 
mechanisms and induce systemic inflammatory 
reaction syndrome, which can ultimately lead to 
multiple organ failure [19-22]. In the present 
study, the improvements in oxidative stress and 
stress hormones observed in the treatment group 
were more obvious than those in the control 
group, suggesting that oxidative damage and 
stress were effectively controlled. Thus, the value 
and curative effect of an insulin micropump 
system in the treatment of DKA were confirmed. 
 
Limitations of the study 
 
Insulin pump treatment is not applicable to 
patients with severe DKA because of their poor 
insulin absorption which arises from circulatory 
failure. Thus, patients with severe DKA were not 
included in this study. The therapeutic effect of 





Patients treated with insulin pump show more 
obvious changes in their comprehensive stress 
state, compared with those treated with 
intravenous instillation of low-dose insulin. Insulin 
pump treatment improves DKA-associated 
indices. Thus, insulin pump treatment, which can 
more effectively relieve the stress state and 
lower blood glucose levels of patients, needs 
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